Rivaroxaban (Xarelto)
Other Medications · Approved since 2011
Description
Rivaroxaban is a direct oral anticoagulant (DOAC) from the factor Xa inhibitor class used for thromboembolism prevention and treatment in colorectal cancer patients. Cancer patients have significantly elevated risk of venous thromboembolism (VTE), and rivaroxaban provides anticoagulation therapy for both prophylaxis and treatment of blood clots in this population. In colorectal cancer, it is particularly relevant for extended prophylaxis following surgical resection and for managing cancer-associated thrombosis.
Mechanism of Action
Rivaroxaban directly and selectively inhibits factor Xa, a key enzyme in the coagulation cascade responsible for converting prothrombin to thrombin. By blocking factor Xa, rivaroxaban prevents thrombin generation and fibrin clot formation, thereby reducing the risk of thrombotic events commonly associated with malignancy and surgical procedures.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Xarelto |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Administration | Oral |
| Year Approved | 2011 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.